These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35280376)

  • 1. Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients.
    Li L; Chen C; Liu C; Niu L; Pan C
    Ann Transl Med; 2022 Feb; 10(4):214. PubMed ID: 35280376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in
    Xiang L; Fu X; Wang X; Li W; Zheng X; Nan K; Tian T
    Front Oncol; 2020; 10():559896. PubMed ID: 33072585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.
    Stein MK; Pandey M; Xiu J; Tae H; Swensen J; Mittal S; Brenner AJ; Korn WM; Heimberger AB; Martin MG
    JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The co-mutation of
    Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H
    J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
    Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
    Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
    J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
    Alborelli I; Bratic Hench I; Chijioke O; Prince SS; Bubendorf L; Leuenberger LP; Tolnay M; Leonards K; Quagliata L; Jermann P; Matter MS
    Lung Cancer; 2020 Nov; 149():84-89. PubMed ID: 32980613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing.
    Zhou C; Chen S; Xu F; Wei J; Zhou X; Wu Z; Zhao L; Liu J; Guo W
    Ann Transl Med; 2021 Sep; 9(18):1437. PubMed ID: 34733989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Signatures of
    Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
    Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
    Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
    Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of the human epidermal growth factor receptor 2 (
    Huang H; Wang Z; Li Y; Zhao Q; Niu Z
    J Gastrointest Oncol; 2021 Apr; 12(2):377-387. PubMed ID: 34012633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.